Carbon dioxide intranasal - Soleno Therapeutics

Drug Profile

Carbon dioxide intranasal - Soleno Therapeutics

Alternative Names: Serenz; Serenz Allergy Relief

Latest Information Update: 10 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Capnia
  • Developer Soleno Therapeutics
  • Class Inorganic carbon compounds; Oxides
  • Mechanism of Action Calcitonin gene-related peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Trigeminal neuralgia
  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic rhinitis; Cluster headache; Trigeminal neuralgia

Most Recent Events

  • 12 Apr 2017 Capnia terminates a phase II trial in Cluster headache in USA (Intranasal) (NCT02381795)
  • 13 May 2016 9195736 - added trial Phase II TN description
  • 21 Dec 2015 Carbon dioxide intranasal - Capnia receives Orphan Drug status for Trigeminal neuralgia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top